Cunningham, D., Sirohi, B., Pluzanska, A., Utracka-Hutka, B., Zaluski, J., Glynne-Jones, R., ...
Background: Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC). The aim of this multicentre, open-label,...
Guo, X, Evans, T.R.J., Somanath, S, Armesilla, A.L., Darling, J.L., Schatzlein, A, ...
Nuclear factor-kappa B (NF-kappaB) is a transcription factor with high transcriptional activity in cancer cells. In this study, we developed a novel enhancer-promoter system, kappaB4-CEA205, in which...
Capecitabine in the treatment of colorectal cancer (2007)
Capecitabine is an oral prodrug of 5-fluorouracil. It is being increasingly used in the treatment of colorectal cancer in both the adjuvant and metastatic settings. This review aims to explore the...
Chemotherapy in metastatic colorectal cancer (2007)
This article aims to provide the reader with a broad overview of the current chemotherapeutic options available for the treatment of patients with metastatic colorectal cancer. The review includes...
Benson, C, White, J, De Bono, J, O'Donnell, A, Raynaud, F, Cruickshank, C, ...
Several schedules of 5-fluorouracil (FU) and irinotecan (IRI) have been shown to improve overall survival in advanced colorectal cancer (CRC). Preclinical evidence suggests that the sequential...
Little, J., Sharp, L., Masson, L.F., Brockton, N.T., Cotton, S.C., Hayes, N.E., ...
Cytochrome P-450 CYP1A1 is involved in the metabolism of polycyclic aromatic hydrocarbons (PAHs) that are derived from meat intake and tobacco smoking. Expression of the CYP1A1 gene is induced by...
Cassidy, J., Douillard, J.Y., Twelves, C., McKendrick, J.J., Scheithauer, W., Bustová, I., ...
Oral capecitabine (Xeloda®) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer. Oxaliplatin-based therapy is becoming standard for Dukes' C colon cancer in...
Chong, G., Bhatnagar, A., Cunningham, D., Cosgriff, T. M., Harper, P. G., Steward, W., ...
Background: The monoclonal antibody 3H1 mimics the external structure of the carcinoembryonic antigen (CEA). It therefore has the potential, via the anti-idiotypic network, to stimulate immune...
Chong, G., Bhatnagar, A., Cunningham, D., Cosgriff, T. M., Harper, P. G., Steward, W., ...
Background: The monoclonal antibody 3H1 mimics the external structure of the carcinoembryonic antigen (CEA). It therefore has the potential, via the anti-idiotypic network, to stimulate immune...
E.F. Duffy, F. Al Touati, S.C. Kehoe, O.A. McLoughlin, L.W. Gill, W. Gernjak, ...
The technical feasibility and performance of photocatalytic TiO2 coatings in batch-process solar disinfection (SODIS) reactors to improve potability of drinking water in developing countries have...
E.F. Duffy, F. Al Touati, S.C. Kehoe, O.A. McLoughlin, L.W. Gill, W. Gernjak, ...
The technical feasibility and performance of photocatalytic TiO2 coatings in batch-process solar disinfection (SODIS) reactors to improve potability of drinking water in developing countries have...
Temporally linked volcanic centres in the Auckland Volcanic Field (2004)
An open access copy of this article is available from the publishers website.
Scheithauer, W., McKendrick, J., Begbie, S., Borner, M., Burns, W. I., Burris, H. A., ...
Background: Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil–leucovorin (5-FU/LV) as first-line treatment for patients with...
Bertelsen, K, Stuart, G, Cassidy, J, Mangioni, C, Simonsen, E, ...
Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European-Canadian Intergroup, have shown superiority, in clinical response...
Díaz-Rubio, E., Evans, T. R. J., Tabernero, J., Cassidy, J., Sastre, J., Eatock, M., ...
Objectives This phase I, dose-escalation study was conducted to determine the recommended dose of intermittent oral capecitabine in combination with a fixed dose of i.v. oxaliplatin. Secondary...
Cassidy, J., Twelves, C., Van Cutsem, E., Hoff, P., Bajetta, E., Boyer, M., ...
Purpose To evaluate the safety profile of capecitabine using data from a large, well-characterized population of patients with metastatic colorectal cancer treated in two phase III studies. In these...
Affleck, D.K., Cassidy, J., Locke, C.A.
An open access copy of this article is available from the publishers website.
Cavill, A.W., Cassidy, J., Brennan, B.J.
An open access copy of this article is available from the publishers website.
Hughes, M. J., Kerr, D. J., Cassidy, J., Soukop, M., McGregor, K., Blackburn, N., ...
Background: In view of the encouraging single agent response rates to interferon and 5-fluorouracil (5-FU) in malignant carcinoid and endocrine pancreatic tumours and the theoretical benefits of...
A phase II study of Tomudex in relapsed epithelial ovarian cancer (1995)
Gore, M. E., Earl, H. M., Cassidy, J., Tattersall, M., Mansi, J., Seymour, L., ...
Chemotherapy administration: Doses, infusions and choice of schedule (1994)
Background: Oncologists are trained to make the best use of all available modes of therapy for patients with cancer. Our current armamentarium of cytotoxic drugs is, however, far from ideal,...
The changing role of surgery in metastatic non-seminomatous germ cell tumour.
Cassidy, J., Lewis, C. R., Kaye, S. B., Kirk, D.
In the last 2 years (1989-1990) we have treated a total of 53 patients with metastatic nonseminomatous germ cell tumours (teratoma). In ten cases surgery to remove residual abdominal masses was...
Phase I and pharmacokinetic study of D-verapamil and doxorubicin.
Bissett, D., Kerr, D. J., Cassidy, J., Meredith, P., Traugott, U., Kaye, S. B.
The calcium antagonist verapamil (a mixture of D- and L-racemers) is a potent modulator of the multi-drug resistance phenotype in vitro at a concentration of 6 microM. Clinical studies have shown...
Jodrell, D. I., Murray, L. S., Reed, N. S., Canney, P. A., Kaye, S. B., Cassidy, J.
Bolus/infusional 5-fluorouracil (5-FU) and folinic acid (FA) is reported to be highly active [partial response (PR) = 54%, median survival 18 months] in patients with metastatic colorectal carcinoma...
Paz-Ares, L., Kunka, R., DeMaria, D., Cassidy, J., Alden, M., Beranek, P., ...
GI147211 is a novel, totally synthetic camptothecin with promising preclinical and early clinical activity. This study was designed to determine the maximum tolerated dose of Gl147211 as a 72-h...
Mackean, M. J., Kerr, D., Lesko, M., Svedberg, A., Hansson, F., Jodrell, D., ...
Thirty-one patients with advanced renal carcinoma or malignant melanoma were treated in the first feasibility study of alpha-interferon (Roferon) and the new oral immunomodulating agent, Linomide....
Mackean, M. J., Cassidy, J., Jodrell, D. I., Paul, J., Reed, N. S., Canney, P. A., ...
We have used a relatively new trial methodology, the group sequential design, to prospectively evaluate two dose levels of bolus/infusional 5-fluorouracil (5-FU) and folinic acid in 192...
Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer.
Ridge, S. A., Sludden, J., Wei, X., Sapone, A., Brown, O., Hardy, S., ...
Individuals with a deficiency in the enzyme dihydropyrimidine dehydrogenase (DPD) may experience severe life-threatening toxicity when treated with 5-fluorouracil (5-FU). As routine measurement of...
Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours.
McLeod, H. L., Sludden, J., Murray, G. I., Keenan, R. A., Davidson, A. I., Park, K., ...
Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme for degradation of 5-fluorouracil (5-FU). DPD activity is highly variable in liver and peripheral mononuclear cells (PMNCs) and it...
Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.
Cassidy, J., Raina, V., Lewis, C., Adams, L., Soukop, M., Rapeport, W. G., ...
Twenty patients receiving a variety of emetogenic cytotoxics (including cisplatin in 5) were given a single i.v. infusion of 40 micrograms kg-1 of BRL43694 (as the hydrochloride salt) in successive...
Benson, C, White, J, Bono, J De, O'Donnell, A, Raynaud, F, Cruickshank, C, ...
Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and 9 to enter clinical trial. Preclinical studies showed antitumour...
Guo, X, Evans, T R J, Somanath, S, Armesilla, A L, Darling, J L, Schatzlein, A, ...
Nuclear factor-kappa B (NF-κB) is a transcription factor with high transcriptional activity in cancer cells. In this study, we developed a novel enhancer–promoter system, κB4-CEA205, in which the...
Cassidy, J, Douillard, J-Y, Twelves, C, McKendrick, J J, Scheithauer, W, Bustová, I, ...
Oral capecitabine (Xeloda®) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer. Oxaliplatin-based therapy is becoming standard for Dukes' C colon cancer in...
Nurgat, Z A, Craig, W, Campbell, N C, Bissett, J D, Cassidy, J, Nicolson, M C
Successful advances in the treatment of advanced malignant diseases rely on recruitment of patients into clinical trials of novel agents. However, there is a genuine concern for the welfare of...
Comparative genomic hybridization and chromosomal instability in solid tumours
Rooney, P H, Murray, G I, Stevenson, D A J, Haites, N E, Cassidy, J, McLeod, H L
Rural factors and survival from cancer: analysis of Scottish cancer registrations
Campbell, N C, Elliott, A M, Sharp, L, Ritchie, L D, Cassidy, J, Little, J
In this survival study 63 976 patients diagnosed with one of six common cancers in Scotland were followed up. Increasing distance from a cancer centre was associated with less chance of diagnosis...
Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034
Bissett, D, McLeod, H L, Sheedy, B, Collier, M, Pithavala, Y, Paradiso, L, ...
The novel folate analogue AG2034, which was designed as an inhibitor of GARFT (glycinamide ribonucleotide formyltransferase), was evaluated in this phase I study under the auspices of The Cancer...
Rural and urban differences in stage at diagnosis of colorectal and lung cancers
Campbell, N C, Elliott, A M, Sharp, L, Ritchie, L D, Cassidy, J, Little, J
There is evidence that patients living in outlying areas have poorer survival from cancer. This study set out to investigate whether they have more advanced disease at diagnosis. Case notes of 1323...
Colorectal cancer genomics: evidence for multiple genotypes which influence survival
Rooney, P H, Boonsong, A, McKay, J A, Marsh, S, Stevenson, D A J, Murray, G I, ...
Colorectal cancer (CRC) is a leading cause of cancer death and the mechanism for variable outcome in this disease is not yet fully understood. It is hypothesized that differences in the genetic...
Impact of deprivation and rural residence on treatment of colorectal and lung cancer
Campbell, N C, Elliott, A M, Sharp, L, Ritchie, L D, Cassidy, J, Little, J
For common cancers, survival is poorer for deprived and outlying, rural patients. This study investigated whether there were differences in treatment of colorectal and lung cancer in these groups....
Bissett, D, Cassidy, J, De Bono, J S, Muirhead, F, Main, M, Robson, L, ...
Thomson, A H, Vasey, P A, Murray, L S, Cassidy, J, Fraier, D, Frigerio, E, ...
Doxorubicin pharmacokinetics were determined in 33 patients with solid tumours who received intravenous doses of 20–320 mg m−2 HPMA copolymer bound doxorubicin (PK1) in a phase I study. Since...
c-erbB-2 is not a major factor in the development of colorectal cancer
McKay, J A, Loane, J F, Ross, V G, Ameyaw, M-M, Murray, G I, Cassidy, J, ...
We have investigated c-erbB-2 protein expression in a large cohort of well-characterized colorectal tumours, and in a subset of lymph node metastases. We have also evaluated a Val655Ile single...
Although significant advances have been made in the treatment of advanced/metastatic colorectal cancer, 5-fluorouracil (5-FU) still forms the basis of chemotherapy. Recently, new 5-FU schedules and...